ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2021
The prevalence of comorbidities in patients with multiple sclerosis: population-based registry data.
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Neuroticism as a Common Factor in Depression and Anxiety Associated with Multiple Sclerosis-A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2024Pooled it
- Type 2 diabetes mellitus in people with multiple sclerosis: a systematic review and meta-analysis.Acta neurologica Belgica · 2026Review
- Prevalence and Risk of Anemia in People With Multiple Sclerosis (MS): A Systematic Review and Meta-Analysis.Anemia · 2026Review
- Use of Real-World Claims Data to Assess the Prevalence of Concomitant Medications to Inform Drug-Drug Interaction Risk in Target Patient Populations.Clinical pharmacology and therapeutics · 2025Article
- The Prevalence of Comorbidities and Their Association With Disability Progression in Individuals With Multiple Sclerosis: A Study From Brazil.International journal of MS care · 2024Article
- [Comorbidities in multiple sclerosis and their influence on the choice of treatment].Revista de neurologia · 2024Review
- Multiple sclerosis and personality traits: associations with depression and anxiety.European journal of medical research · 2024Article
- Investigation of differences between chronological and vascular age in persons with multiple sclerosis.PloS one · 2024Article
- Protocol of a prospective multicenter study on comorbidity impact on multiple sclerosis and antibody-mediated diseases of the central nervous system (COMMIT).Frontiers in immunology · 2024Article
- The Importance of Managing Modifiable Comorbidities in People with Multiple Sclerosis: A Narrative Review.Journal of personalized medicine · 2023Review
- The Prevalence of Diabetes Mellitus Type II (DMII) in the Multiple Sclerosis Population: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2023Review
- The impact of the comorbid seizure/epilepsy on the health related quality of life in people with multiple sclerosis: an international multicentric study.Frontiers in immunology · 2023Article
- Recent progress in epidemiology, clinical features, and therapy of multiple sclerosis in China.Therapeutic advances in neurological disorders · 2023Review
- Occurrence of malignant diseases in patients with multiple sclerosis: population-based MS Registry data.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Article
- Cerebral blood flow dependency on systemic arterial circulation in progressive multiple sclerosis.European radiology · 2022Article
- Adherence to Therapy in Patients with Multiple Sclerosis-Review.International journal of environmental research and public health · 2022Review
- Treatment patterns in pediatric patients with multiple sclerosis in Germany-a nationwide claim-based analysis.Therapeutic advances in neurological disorders · 2021Article
- The Role of Clinical Pharmacists in Patient-Centric Comprehensive Multiple Sclerosis Care.International journal of MS careArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundComorbidities occur frequently in persons with multiple sclerosis (MS). The aim of the present study was to determine the prevalence of the most common comorbidities in the population of MS patients in Belgrade, Serbia. MATERIAL AND
methodsData on diagnosed and fully documented comorbidities were taken from the Belgrade MS population registry. The list of explored comorbidities included cardiovascular, malignant, and autoimmune diseases; psychiatric disorders; epilepsy; and type 2 diabetes. In the data analysis, crude, age- and gender-specific, and age-adjusted prevalence was calculated. Additionally, comorbidities were analyzed in patients with various MS phenotypes.
resultsThe most prevalent group of comorbidities were psychiatric (prevalence (Prev) = 20.59%, 95% CI 19.10-22.17) and cardiovascular comorbidities (Prev = 15.23%, 95% CI 13.93-16.63). The most prevalent single comorbidities were depression (Prev = 11.82%, 95% CI 10.64-13.11) and hypertension (Prev = 11.41%, 95% CI 10.25-12.68). Type 2 diabetes was significantly more prevalent in patients with primary progressive MS compared with the patients with relapsing-remitting and secondary progressive MS (p < 0.001). We found statistically significant positive correlation between number of comorbidities and progression index (p < 0.001). Patients treated with disease-modifying therapies (DMTs) had significantly higher risk of developing comorbidity, after treatment initiation, compared with those who were untreated (p = 0.001).
conclusionsOur study demonstrated high prevalence of comorbidities in persons with MS, with psychiatric and cardiovascular diseases being the most common. Furthermore, our findings confirmed the association of comorbidities with progression of disability and emphasized their role in treatment decision-making in MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.